NASDAQ · Diagnostics & Research · USD
XWELL, Inc. (XWEL) Stock Analysis
XWELL, Inc. (XWEL) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
XWEL Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.68
- Previous Close
- $0.65
- Day's Range
- 0.66–0.80
- 52-Week Range
- 0.26–2.20
- Volume
- 167.06K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.94
Valuation
- Market Cap
- $6.99M
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 0.25
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −5.24
Financials (FY)
- Revenue (FY)
- $29.21M−13.83%
- Net Income (FY)
- −$16.99M
- Profit marginThe share of revenue left as profit after all costs and taxes.
- −82.90%
- Shares Outstanding
- 9.97M
- 1-Year Return
- −28.49%
Dividend and dates
- Avg Volume
- 38.32K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, XWEL closed at $0.70, −28.49% over 1 year.
XWELL, Inc. (XWEL) has a market capitalization of $6.99M.
In fiscal 2025, XWEL reported revenue of $29.21M.
XWEL Stock Return by Calendar Year
XWELL, Inc. (XWEL) 10-year return: what $10,000 became
- 1 year
- $10,000 $7,151
- −28.49%
- 5 years
- $10,000 $245
- −97.55%
- 10 years
- $10,000 $2
- −99.98%
If you had invested $10,000 in XWELL, Inc. (XWEL) 10 years ago, at the close on October 21, 2016, it would have been worth $2 at the close on October 21, 2026: −99.98% in total, −57.69% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +52.35% |
| 2025 | −69.54% |
| 2024 | −13.22% |
| 2023 | −75.83% |
| 2022 | −82.18% |
| 2021 | +69.75% |
| 2020 | −40.80% |
| 2019 | −79.06% |
| 2018 | −88.32% |
| 2017 | −35.68% |
| 2016 (partial year) | +1.43% |
As of October 21, 2026.
XWEL Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $29.21M | −$16.99M | −58.2% |
| 2024 | $33.90M | −$16.85M | −49.7% |
| 2023 | $30.11M | −$27.74M | −92.1% |
| 2022 | $55.94M | −$32.84M | −58.7% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $29.21M | $7.51M | −$9.36M | −$16.99M | −58.2% |
| 2024 | $33.90M | $8.92M | −$12.10M | −$16.85M | −49.7% |
| 2023 | $30.11M | $3.68M | −$19.30M | −$27.74M | −92.1% |
| 2022 | $55.94M | $12.05M | −$24.55M | −$32.84M | −58.7% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
XWEL Valuation vs Diagnostics & Research Median
Median of 45 stocks| Metric | XWEL | Diagnostics & Research median | vs median |
|---|---|---|---|
| P/S ratio | 0.25 | 5.23 | 0.0x the median |
| Profit margin | −82.90% | −0.93% | 82.0 pts below |
Medians across 45 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Diagnostics & Research Stocks
Thermo Fisher Scientific Inc.
$256.61B
DHRDanaher Corporation
$164.40B
NTRANatera, Inc.
$59.59B
AAgilent Technologies, Inc.
$50.12B
IQVIQVIA Holdings Inc.
$45.53B
WATWaters Corporation
$44.92B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B